CRISPR gene editing stories

Aug 2, 2026

CRISPR makes prostate cancer vulnerable to immunotherapy in mice

Scientists used CRISPR gene editing to make prostate cancer cells easier for the immune system to detect and destroy, dramatically improving immunotherapy effectiveness in mice.

Aug 2, 20261 source

Jul 2, 2026

FDA Expands Casgevy Gene Therapy Approval to Children as Young as Two with Sickle Cell Disease and Beta Thalassemia

The FDA has approved Vertex Pharmaceuticals' Casgevy (exagamglogene autotemcel) for patients aged two years and older with sickle cell disease and transfusion-dependent beta thalassemia, expanding from the previous minimum age of 12 years. The approval was granted under the agency's Commissioner's National Priority Voucher program.

Jul 2, 20263 sources

Apr 27, 2026

Intellia Reports Positive Pivotal Trial Results for CRISPR-Based Treatment of Rare Swelling Disease

Intellia Therapeutics announced that its CRISPR-based gene editing treatment reduced swelling attacks in a pivotal trial for hereditary angioedema, a rare genetic disease. The results advance the CRISPR field's one-and-done treatment approach toward potential regulatory approval.

Apr 27, 20261 source